Abstracts Archive - Page 1753 of 2607 - ACR Meeting Abstracts

Abstract Number: 2312 • 2016 ACR/ARHP Annual Meeting
Anti-TIF1-Gamma Antibodies Are Not Associated with Other Paraneoplastic Rheumatic Syndromes Than Dermatomyositis
Paulius Venalis¹, Sandra Selickaja^2,3, Karin Lundberg⁴, Rita Rugiene^5,6 and Ingrid E. Lundberg⁷, ¹Karolinska Institutet, Stockholm, Sweden, ²Vilnius University, Center of Rheumatology;, Vilnius, Lithuania, ³State Research Institute for Innovative Medicine, Vilnius, Lithuania, ⁴Rheumatology Unit, Department, Karolinska Institute, Stockholm, Sweden, ⁵Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania, ⁶State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania, ⁷Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: An association between cancer and dermatomyositis (DM), referred to as cancer-associated myositis, is well recognized and clinically important. The overall cancer risk is up…
Abstract Number: 2313 • 2016 ACR/ARHP Annual Meeting
Profile of Cardiovascular Burden in Myositis: A Case-Control Study
Alexander G.S. Oldroyd¹, Robert Cooper², Benjamin Parker³, Ian N. Bruce¹, Paul New⁴ and Hector Chinoy⁵, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Department of Musculoskeletal Biology, University of Liverpool, Liverpool, United Kingdom, ³Centre for Musculoskeletal Research, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ⁴Institute of Ageing and Chronic Disease, The University of Liverpool, Liverpool, United Kingdom, ⁵Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
Background/Purpose: Research has indicated that cardiovascular disease is the leading cause of death in the Idiopathic Inflammatory Myopathies (IIM). Only a small number of studies…
Abstract Number: 2314 • 2016 ACR/ARHP Annual Meeting
Anti-Mi2 Dermatomyositis Revisited: Pure DM Phenotype with Muscle Fiber Necrosis and High Risk of Malignancy
Océane Landon-Cardinal¹, Grégoire Monseau², Yoland Schoindre³, Aude Rigolet¹, Nicolas Champtiaux¹, Baptiste Hervier¹, Agathe Masseau⁴, Eric Hachulla⁵, Thomas Papo⁶, Benjamin Terrier⁷, Alain Meyer⁸, Jean-Emmanuel Kahn³, François Maurier⁹, Francis Gaches¹⁰, Emmanuelle Salort-Campana¹¹, Thierry Zenone¹², Nathalie Costedoat-Chalumeau⁷, Florian Perez¹³, Maxime Samson¹⁴, Anne-Marie Piette³, Guillaume Moulis¹⁰, Sylvain Audia¹⁵, Séverine Genot¹⁶, Nicolas Schleinitz¹⁷, Guillaume Lefevre⁵, Laurence Verneuil¹⁸, Olivier Benveniste¹⁹, Yves Allenbach¹ and Boris Bienvenu²⁰, ¹Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ²Internal Medicine, Caen University Hospital, Caen, France, ³Internal Medicine, Foch Hospital, Suresnes, France, ⁴Internal Medicine, Nantes University Hospital, Nantes, France, ⁵Internal Medicine, Lille University Hospital, Lille, France, ⁶Bichat University Hospital - Internal Medicine, Paris, France, ⁷Internal Medicine, Cochin University Hospital, Paris, France, ⁸Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁹Internal Medicine, Sainte-Blandine de Metz Hospital, Metz, France, ¹⁰Internal Medicine, Toulouse University Hospital, Toulouse, France, ¹¹Neurology, La Timone University Hospital, Marseille, France, ¹²Internal Medicine, Valence Hospital, Valence, France, ¹³Neurology, Albi Hospital, Albi, France, ¹⁴Dijon University Hospital, Dijon, France, ¹⁵Internal Medicine, Dijon University Hospital, Dijon, France, ¹⁶Internal Medicine, Martigues Hospital, Martigues, France, ¹⁷La Timone University Hospital, Marseille, France, ¹⁸Dermatology, Caen University Hospital, Caen, France, ¹⁹Pitié-Salpêtrière University Hospital, Paris, France, ²⁰Caen University Hospital, Caen, France
Background/Purpose: Anti-Mi2 autoantibodies (Aabs) have been proposed to be highly specific for dermatomyositis (DM) and to be associated with a DM classical phenotype consisting of…
Abstract Number: 2315 • 2016 ACR/ARHP Annual Meeting
The Effectiveness of Social Media in Recruiting for Rare Rheumatic Diseases
Adam Schiffenbauer¹, Lisa G. Rider², Sara Faghihi-Kashani³, Komal Patel⁴ and Frederick W. Miller⁵, ¹Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ³Environmental Autoimmunity Group, National Institute of Environmental Health, Bethesda, MD, ⁴Social and Scientific Systems, Inc., Bethesda, MD, ⁵Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, NIH, Bethesda, MD
Background/Purpose: Clinical research is dependent on being able to recruit and enroll appropriate patients in sufficient numbers to make robust conclusions. For many diseases it…
Abstract Number: 2316 • 2016 ACR/ARHP Annual Meeting
Successful Treatment of Statin-Induced Autoimmune Myopathy without Corticosteroids
Geneviève Oligny Longpré¹, Yves Troyanov¹, Marvin J. Fritzler², José Ferreira¹, Ira N. Targoff³, Hélène Couture⁴, Océane Landon-Cardinal¹, Eric Rich¹, Josiane Bourré-Tessier⁵, Anne-Marie Mansour¹, Julie Drouin¹, Sandra Chartrand¹, Edith Villeneuve¹, Jean-Richard Goulet¹, Benjamin Ellezam⁶, Ana Maria Tsanaclis¹, Vincent Morin¹, Marie-Pierre Fournier-Gosselin¹ and Jean-Luc Senécal¹, ¹Université de Montréal, Montréal, QC, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³University of Oklahoma, Oklahoma City, OK, ⁴Université Laval, Québec, QC, Canada, ⁵Université de Montréal, Montreal, QC, Canada, ⁶Centre hospitalier universitaire Ste-Justine, Montréal, QC, Canada
Methods: Our study included all patients from the Université de Montréal AIM cohort (comprising four academic hospitals) with a documented anti-3-hydroxy-3-methylglutaryl-CoA reductase (anti-HMGCR) autoantibody. We selected…
Abstract Number: 2317 • 2016 ACR/ARHP Annual Meeting
Preliminary Validation of a Magnetic Resonance Imaging-Based Inflammatory Scoring System in Adult Myositis
Nicolo Pipitone¹, Antonella Notarnicola^2,3, Arnaldo Scardapane⁴, Lucia Spaggiari⁵, Gabriele Levrini⁶, Florenzo Iannone⁷, Carlo Salvarani⁸, Giovanni Lapadula⁹, Ingrid E. Lundberg², Pierpaolo Pattacini¹⁰ and Giulio Zuccoli¹¹, ¹Rheumatology, Arcispedale S. M. Nuova, Reggio Emilia, Italy, ²Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology, Bari University, Bari, Italy, ⁴Radiology, University of Bari, Bari, Italy, ⁵Radiology, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ⁶Arcispedale S Maria Nuova, Reggio Emilia, Italy, ⁷Bari University, Rheumatology, Bari, Italy, ⁸Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁹Rheumatology Unit, University of Bari, Bari, Italy, ¹⁰Radiology, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy, ¹¹Children's Hospital of Pittsburgh, Pittsburgh, PA
Background/Purpose: in patients with active myositis, magnetic resonance imaging (MRI) often demonstrates muscle edema thought to represent active inflammation. An MRI-based muscle inflammatory scoring system…
Abstract Number: 2318 • 2016 ACR/ARHP Annual Meeting
Real World Use of the Myositis Autoantibody Panel
Jason Weiner¹, Ryan Jessee², Robert T. Keenan³, Michael Datto⁴ and Lisa Criscione-Schreiber⁵, ¹Division of Rheumatology, Duke University, Durham, NC, ²Division of Internal Medicine, Duke University, Durham, NC, ³Rheumatology, Duke University, Durham, NC, ⁴Division of Pathology, Duke University, Durham, NC, ⁵Division of Rheumatology, Department of Medicine, Duke University, Durham, NC
Background/Purpose: The identification of myositis specific and associated autoantibodies occurring in idiopathic inflammatory myopathies (IIMs) has improved classification and prognosis determinations. With commercial availability, these…
Abstract Number: 2319 • 2016 ACR/ARHP Annual Meeting
High Prevalence of Asymptomatic Vertebral Fractures in Inflammatory Myositis
Latika Gupta, Sukesh Edavalath, Ramnath Misra and Able Lawrence, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Patients with inflammatory myositis have increased prevalence of symptomatic fractures. Early detection of asymptomatic vertebral fractures may help in their prevention. We studied the…
Abstract Number: 2320 • 2016 ACR/ARHP Annual Meeting
Oropharyngeal Dysphagia in Autoimmune Myositis
Jessica Nehme¹, Jean-Paul Makhzoum², Josiane Bourré-Tessier³, Yves Troyanov⁴, Marianne Landry¹, Océane Landon-Cardinal⁵, Marvin J. Fritzler⁶, Anne-Marie Mansour⁷, Eric Rich⁸, Jean-Richard Goulet⁹, Tamara Grodzicky¹⁰, Edith Villeneuve², Frédéric Massicotte¹¹, Florence Weber¹², Martial Koenig¹³, Sylvie Desmarais¹⁴, José Ferreira², Benjamin Ellezam¹⁵, Ira N. Targoff¹⁶ and Jean-Luc Senécal², ¹Université de Montréal, Montreal, QC, Canada, ²Université de Montréal, Montréal, QC, Canada, ³Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ⁴Rheumatology, Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada, ⁵Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ⁶Medicine, University of Calgary, Calgary, AB, Canada, ⁷medicine, Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada, ⁸Div of Rheumatology, C H Univ de Montreal, Montreal, QC, Canada, ⁹246 av Edison, CHUM - H, Saint-Lambert, QC, Canada, ¹⁰Rheumatology, Hôpital Notre-Dame du CHUM, Montreal, QC, Canada, ¹¹Hôpital Notre-Dame, Montr, QC, Canada, ¹²Hôpital St-Luc, Montreal, QC, Canada, ¹³Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, ¹⁴Centre Hospitalier Pierre-Boucher, Longueuil, QC, Canada, ¹⁵Hôpital Ste-Justine, Montreal, QC, Canada, ¹⁶University of Oklahoma, Oklahoma City, OK
Background/Purpose: Oropharyngeal dysphagia (OPD) is an ominous finding in autoimmune myositis (AIM), yet few studies have evaluated the disease subsets at higher risk for this…
Abstract Number: 2321 • 2016 ACR/ARHP Annual Meeting
Early Damage and Mortality in a Cohort of Patients with Myositis Followed up to 20 Years
Sara Guerreiro Castro¹, Pedro Mota² and David A. Isenberg³, ¹Autoimmune Diseases Unit - Serviço Medicina 7.2, Hospital Curry Cabral, Centro Hospitalar Lisboa Central, Lisbon, Portugal, ²Internal Medicine, Hospital da Luz, Lisbon, Portugal, ³Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of rare diseases, including dermatomyositis (DM), polymyositis (PM) and juvenile dermatomyositis (JDM). Patients often need long-term treatment…
Abstract Number: 2322 • 2016 ACR/ARHP Annual Meeting
The Clinical Significance of Curvilinear Bodies on Ultrastructural Examination of Muscle
Thomas Khoo¹, Sophia Otto², Barbara Koszyka², Caroline Smith², Peter Blumbergs³, Sue Lester⁴ and Vidya Limaye⁵, ¹Medical Student, University of Adelaide, Adelaide, Australia, ²Anatomical Pathology, SA Pathology, Adelaide, Australia, ³Pathology, University of Adelaide, Adelaide, Australia, ⁴Rheumatology, The Queen Elizabeth Hospital, Adelaide, Australia, ⁵Rheumatology, Royal Adelaide Hospital, Adelaide, Australia
Background/Purpose: The electronic database of muscle biopsies reported in the Anatomical Pathology Laboratory, SA Pathology was searched from 2006 to the present, to identify biopsies…
Abstract Number: 2323 • 2016 ACR/ARHP Annual Meeting
Evaluation of Case-Finding Algorithms for Identification of Patients with Dermatomyositis
Kevin Byram¹ and Narender Annapureddy², ¹Internal Medicine, Vanderbilt University, Nashville, TN, ²Rheumatology and Immunology, Vanderbilt University, Nashville, TN
Background/Purpose: In order to enable meaningful clinical care and research, accurate algorithms are needed to identify patients with dermatomyositis (DM). In this study, we aimed…
Abstract Number: 2324 • 2016 ACR/ARHP Annual Meeting
Effects of 12 Weeks Low-Intensity Blood-Flow Restricted Resistance Training on Knee Extensor Strength in Patients with Sporadic Inclusion Body Myositis
Anders Nørkjær Jørgensen¹, Per Aagaard¹, Mette Christiansen¹, Ulrik Frandsen¹ and Louise Pyndt Diederichsen², ¹University of Southern Denmark, Odense, Denmark, ²Rheumatology, Odense University Hospital, Odense, Denmark
Background/Purpose: Sporadic inclusion body myositis (sIBM) represents a progressive inflammatory muscle disease, which causes severe loss in skeletal muscle mass and strength, especially in the…
Abstract Number: 2325 • 2016 ACR/ARHP Annual Meeting
ANTI-Hmgcr Antibodies Demonstrate High Diagnostic VALUE in the Diagnosis of Immune Mediated Necrotizing Myopathy Following Statin Exposure
Ora Shovman¹, Boris Gilburd², Chen Chayat³, Chelsea Bentow⁴, Michael Mahler⁴ and Yehuda Shoenfeld^1,5, ¹Zabludowitz Center for Autoimmune Diseases Sheba Medical Center, Zabludowitz Center for Autoimmune Diseases Sheba Medical Center, 52621, Tel Hashomer, Israel, Ramat Gan, Israel, ²Zabludowitz Center for Autoimmune Diseases Sheba Medical Center, Zabludowitz Center for Autoimmune Diseases Sheba Medical Center, 52621, Tel Hashomer, Israel, Ramat-Gan, Israel, ³Zabludowitz Center for Autoimmune Diseases Sheba Medical Center, 52621, Tel Hashomer, Israel, Ramat Gan, Israel, ⁴Research and Development, Inova Diagnostics, San Diego, CA, ⁵Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, Tel-Aviv, Israel
Background/Purpose: Anti-HMGCR antibodies represent a characteristic serological feature of statin-exposed and statin-unexposed patients with immune mediated necrotizing myopathy (IMNM). We assessed anti-HMGCR antibodies in patients…
Abstract Number: 2326 • 2016 ACR/ARHP Annual Meeting
Intravenous Cyclophosphamide Followed By Oral Immunosuppressive Treatment Versus Rituximab in Inflammatory Myopathy-Related Interstitial Lung Disease
Vincent Langlois¹, Kuberaka Mariampillai², Nicolas Champtiaux³, Marie-Laure Chabi⁴, Yurdagul Uzunhan⁵, Eric Hachulla⁶, Olivier Benveniste⁷ and Baptiste Hervier³, ¹Internal Medicine, University Hospital, Rouen, France, ²Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Department of Internal Medicine and Clinical Immunology, Hospital University Department: inflammation, immunopathology and biotherapy (DHU i2B), Paris, France, Paris, France, ³Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ⁴Radiology department, APHP, Hôpital Pitié Salpêtrière, Paris, France, ⁵Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ⁶Internal Medicine, Lille University Hospital, Lille, France, ⁷Pitié-Salpêtrière University Hospital, Paris, France
Background/Purpose: Interstitial lung disease (ILD) associated with inflammatory myopathy (IM) has a poor prognosis and requires specific treatments. Intravenous Cyclophosphamide (CYC) is one of the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].